TRX 518

Drug Profile

TRX 518

Alternative Names: Anti-GITR monoclonal antibody - Leap Therapeutics; Anti-TNFRSF18 monoclonal antibody; TRX518

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tolerx
  • Developer GITR Inc; Leap Therapeutics
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action TNFRSF18 protein stimulants; Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Malignant melanoma; Viral infections

Most Recent Events

  • 08 Aug 2018 Updated efficacy data from a phase I trial in Solid tumours released by Leap Therapeutics
  • 23 Jul 2018 Leap Therapeutics collaborates with Merck KGaA and Pfizer for a phase I/II trial in Solid tumours
  • 23 Jul 2018 Leap Therapeutics in collaboration with Merck KGaA and Pfizer plans a phase I/II trial for Solid tumors (Late-stage disease, Combination therapy) in first quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top